Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.

Date publication

avril 2021

Journal

Clinical genitourinary cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel , Pr NERICH Virginie , Dr THIERY-VUILLEMIN Antoine , Pr KLEINCLAUSS François

Tous les auteurs :
Pelloux-Prayer R, Schiele P, Oudard S, Gravis G, Kleinclauss F, Crehange G, Hennequin C, Morgans AK, Geoffrois L, Limat S, Thiery-Vuillemin A, Nerich V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33962909

Résumé

The optimal therapeutic strategies for patients with metastatic hormone-sensitive prostate cancer (mHSPC) followed by metastatic castrate-resistant prostate cancer (mCRPC), in terms of cost and effectiveness, remains unknown. This study aims to compare the cost-effectiveness of various potential strategies, from the start of first-line treatment in mHSPC to the death of the patients.

Mots clés

Castrate-resistant, Hormone-sensitive, Metastatic, Prostate cancer, cost-effectiveness analysis

Référence

Clin Genitourin Cancer. 2021 Apr 5;: